AbCellera Biologics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABCL Nasdaq 8731 https://www.abcellera.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbCellera Biologics Inc

Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19 - Apr 5th, 2021 6:00 pm
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration - Apr 1st, 2021 1:00 pm
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Cut Their EPS Forecasts Substantially - Apr 1st, 2021 9:38 am
AbCellera Reports Full Year 2020 Business Results - Mar 29th, 2021 8:05 pm
Analysts See an ‘Attractive Entry Point’ in These 3 Stocks - Mar 25th, 2021 3:51 pm
Billionaire Masayoshi Son’s Top 10 Stock Picks for 2021 - Mar 16th, 2021 4:51 pm
What Percentage Of AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Do Insiders Own? - Mar 13th, 2021 6:00 am
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19 - Mar 10th, 2021 4:21 pm
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients - Mar 5th, 2021 8:30 pm
15 Fastest Growing Biotech Companies in the US - Feb 27th, 2021 2:23 pm
AbCellera to Present at the SVB Leerink Global Healthcare Conference - Feb 17th, 2021 9:05 pm
AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer - Feb 11th, 2021 9:05 pm
IPO Stock Returns Bullish Gains After Lilly-Partnered Covid Drug Nabs OK - Feb 10th, 2021 9:15 pm
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19 - Feb 10th, 2021 1:26 am
AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call - Feb 3rd, 2021 9:05 pm
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19 - Jan 27th, 2021 12:22 pm
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70% - Jan 26th, 2021 12:09 pm
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents - Jan 21st, 2021 1:27 pm
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology - Jan 19th, 2021 9:41 pm
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico - Dec 21st, 2020 2:00 pm